8-K: AN2 Therapeutics Restructures Major Investor's Holdings with Pre-Funded Warrants

AN2 Therapeutics, Inc. has entered into exchange agreements with Coastlands Capital Partners LP, converting 2.8 million shares of common stock into pre-funded warrants to manage beneficial ownership.

Summary

• AN2 Therapeutics, Inc. executed two exchange agreements with Coastlands Capital Partners LP.
• On June 17, 2025, Coastlands Capital exchanged 2,500,000 shares of AN2 Therapeutics' common stock for a pre-funded warrant to acquire 2,500,000 shares of common stock.
• On June 19, 2025, an additional 300,000 shares of common stock were exchanged for a pre-funded warrant to acquire 300,000 shares.
• In total, 2,800,000 shares of common stock were exchanged for pre-funded warrants covering the same number of shares.
• The pre-funded warrants have an exercise price of $0.00001 per underlying share and do not expire until fully exercised.
• The warrants include a beneficial ownership blocker, preventing exercise if it would cause Coastlands Capital's aggregate beneficial ownership to exceed 9.99% of the company's outstanding common stock, though this percentage can be increased to 19.99% after 61 days' notice.
• The warrants were issued without registration, relying on the exemption under Section 3(a)(9) of the Securities Act of 1933.

Sentiment

Score: 5

Explanation: The document is a factual report of a financial transaction, presenting neutral information without explicit positive or negative framing. It describes a restructuring of an existing investor's holdings rather than a new capital raise or operational performance.

Positives

• Allows a significant investor (Coastlands Capital) to maintain an economic interest in the company while potentially managing their beneficial ownership percentage below certain thresholds (e.g., 10% for Section 13(d) reporting or 15% for Delaware Section 203 "interested stockholder" status), offering flexibility for both the company and the investor.
• The warrants are "pre-funded," meaning the capital associated with these shares has already been received by the company, so this transaction does not represent new dilution from a capital raise perspective.
• The structure provides long-term flexibility for Coastlands Capital to convert to common stock without an expiration date.

Negatives

• The conversion of common stock into warrants, even pre-funded, could be perceived as a complex financial maneuver that might obscure the true nature of a large investor's holdings or intentions.
• While not new dilution, the potential future exercise of these warrants could still increase the number of outstanding common shares, potentially impacting per-share metrics if not already accounted for in fully diluted share counts.

Risks

• Beneficial Ownership Limitations: The warrants contain a beneficial ownership blocker (initially 9.99%, adjustable to 19.99%) which prevents the holder from exercising if it would cause their aggregate beneficial ownership to exceed this threshold. This could limit the holder's ability to fully convert their warrants into common stock at any given time.
• Company's Obligation to Deliver Shares: The company has an absolute and unconditional obligation to issue and deliver warrant shares upon exercise, subject to certain limitations, and failure to do so within the standard settlement period could result in "Buy-In" remedies for the holder.
• Regulatory Compliance: The issuance relies on Section 3(a)(9) exemption, which requires specific conditions (e.g., no remuneration for solicitation). Any failure to meet these conditions could have regulatory implications.
• Impact of Corporate Events: The exercise price and number of warrant shares are subject to adjustment based on corporate events like stock dividends, splits, or fundamental transactions, which could introduce complexity.

Future Outlook

The document primarily reports a completed financial transaction and does not provide specific forward-looking statements or guidance regarding the company's future operational or financial performance. The warrants are exercisable at any time until fully exercised, indicating a long-term potential for conversion.

Industry Context

This type of equity restructuring, involving the exchange of common stock for pre-funded warrants, is a financial strategy often employed by companies and large investors to manage beneficial ownership thresholds and regulatory reporting requirements, such as those under Section 13(d) of the Exchange Act. It allows a significant investor to maintain an economic interest while potentially avoiding certain 'interested stockholder' classifications or reporting burdens, which can be a common consideration in the biotechnology or pharmaceutical industry where capital raises and significant investor stakes are frequent.

Comparison to Industry Standards

• NA. This document details a specific financial transaction between the company and a single investor, rather than presenting operational or financial results that can be benchmarked against industry peers or global standards. The structure of pre-funded warrants with beneficial ownership blockers is a known financial instrument, but its specific application here is unique to the company's and investor's circumstances.

Corporate Governance

Related Party Transactions

• The exchange agreements were entered into with Coastlands Capital Partners LP, a significant holder of the company's common stock, which can be considered a related party transaction due to the nature of their existing investment.

Stakeholder Impact

• Shareholders: The transaction restructures a significant investor's holdings. While the warrants are pre-funded (meaning capital was already received), the future exercise of these warrants will increase the number of outstanding common shares, potentially impacting per-share metrics if not already fully diluted. The beneficial ownership blocker affects how a large investor's stake is managed.
• Investors: Provides insight into how a major investor is managing its stake in the company, potentially signaling long-term commitment while managing regulatory thresholds.

Next Steps

• The pre-funded warrants are exercisable at any time until fully exercised by Coastlands Capital Partners LP.
• Coastlands Capital Partners LP may increase or decrease its beneficial ownership percentage to a maximum of 19.99% effective 61 days after providing notice to the company.

Key Dates

Keywords

AN2 Therapeutics, Coastlands Capital Partners, Pre-Funded Warrants, Equity Exchange, SEC Filing, 8-K, Beneficial Ownership, Section 13(d), Section 3(a)(9), Corporate Governance, Stock Warrants, Capital Structure